A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

NCT05190471 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory

Interventions

DRUG: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
DRUG: Decitabine (in combination with BP1002)

Sponsor

Bio-Path Holdings, Inc.